News Focus
News Focus
icon url

DewDiligence

10/28/22 12:03 PM

#244345 RE: Biowatch #244344

Only in the short-run. Within a few quarters, RVNC's Daxxify sales will swamp its dermal-filler sales. Daxxify will also have a much higher profit margin than RVNC's dermal fillers.